Aurora Cannabis (ACB) Downgraded to D+ at TheStreet

TheStreet downgraded shares of Aurora Cannabis (NYSE:ACB) from a c rating to a d+ rating in a report published on Monday, February 25th. Several …

Aurora Cannabis Inc logoTheStreet downgraded shares of Aurora Cannabis (NYSE:ACB) from a c rating to a d+ rating in a report published on Monday, February 25th.

Several other analysts have also weighed in on ACB. GMP Securities reissued a hold rating and issued a $9.50 price objective on shares of Aurora Cannabis in a report on Tuesday, February 12th. Seaport Global Securities assumed coverage on Aurora Cannabis in a report on Thursday, February 21st. They set a neutral rating for the company. Finally, Jefferies Financial Group assumed coverage on Aurora Cannabis in a report on Monday, February 25th. They set a buy rating for the company. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $9.50.

Shares of NYSE:ACB traded down $0.08 during trading on Monday, hitting $8.99. The company’s stock had a trading volume of 56,250,495 shares, compared to its average volume of 29,169,904. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.50 and a current ratio of 3.31. Aurora Cannabis has a fifty-two week low of $4.05 and a fifty-two week high of $12.52. The stock has a market cap of $8.06 billion, a price-to-earnings ratio of 74.92 and a beta of 2.90.

Aurora Cannabis (NYSE:ACB) last released its quarterly earnings results on Monday, February 11th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The business had revenue of $41.00 million for the quarter. Aurora Cannabis had a positive return on equity of 3.95% and a negative net margin of 57.54%. On average, equities research analysts predict that Aurora Cannabis will post -0.17 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Financial Advocates Investment Management bought a new position in Aurora Cannabis in the 4th quarter worth approximately $74,000. Flagship Harbor Advisors LLC bought a new position in Aurora Cannabis in the 4th quarter worth approximately $26,000. Advisory Services Network LLC bought a new position in Aurora Cannabis in the 4th quarter worth approximately $29,000. Trustcore Financial Services LLC bought a new position in Aurora Cannabis in the 4th quarter worth approximately $33,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Aurora Cannabis in the 4th quarter worth approximately $36,000. 8.16% of the stock is owned by institutional investors.

About Aurora Cannabis

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Read More: What are the reasons investors use put options?

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Jefferies Financial Group Reiterates Buy Rating for Aurora Cannabis (ACB)

Jefferies Financial Group restated their buy rating on shares of Aurora Cannabis (TSE:ACB) in a research report released on Monday, February 25th.

Aurora Cannabis Inc logoJefferies Financial Group restated their buy rating on shares of Aurora Cannabis (TSE:ACB) in a research report released on Monday, February 25th. They currently have a C$12.00 target price on the stock.

ACB has been the subject of a number of other research reports. Eight Capital cut their price target on Aurora Cannabis from C$17.00 to C$15.00 in a research note on Wednesday, January 9th. Seaport Global Securities reissued a neutral rating on shares of Aurora Cannabis in a report on Thursday, February 21st. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of C$13.50.

Shares of ACB stock traded down C$0.10 during midday trading on Monday, reaching C$11.92. 20,566,041 shares of the stock were exchanged, compared to its average volume of 18,717,105. The company has a debt-to-equity ratio of 8.08, a quick ratio of 1.89 and a current ratio of 3.31. Aurora Cannabis has a 1 year low of C$5.29 and a 1 year high of C$16.24. The company has a market capitalization of $10.77 billion and a price-to-earnings ratio of -120.40.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Monday, February 11th. The company reported C($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.06) by C$0.01. The business had revenue of C$54.18 million during the quarter, compared to the consensus estimate of C$52.13 million. Sell-side analysts forecast that Aurora Cannabis will post 0.0300000005785921 earnings per share for the current year.

A hedge fund recently bought a new stake in Aurora Cannabis stock. Gulf International Bank UK Ltd acquired a new stake in shares of Aurora Cannabis Inc (TSE:ACB) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,669 shares of the company’s stock, valued at approximately $112,000.

Aurora Cannabis Company Profile

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis, and hemp production, derivatives, home cultivation, wholesale and retail distribution.

Recommended Story: Cost of Equity For A Business, Investors

Analyst Recommendations for Aurora Cannabis (TSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Investors Buy Aurora Cannabis (ACB) on Weakness

Investors bought shares of Aurora Cannabis Inc (NYSE:ACB) on weakness during trading on Thursday. $131.48 million flowed into the stock on the …

Aurora Cannabis logoInvestors bought shares of Aurora Cannabis Inc (NYSE:ACB) on weakness during trading on Thursday. $131.48 million flowed into the stock on the tick-up and $92.16 million flowed out of the stock on the tick-down, for a money net flow of $39.32 million into the stock. Of all stocks tracked, Aurora Cannabis had the 22nd highest net in-flow for the day. Aurora Cannabis traded down ($0.08) for the day and closed at $8.99

ACB has been the subject of a number of research analyst reports. Seaport Global Securities initiated coverage on Aurora Cannabis in a report on Thursday, February 21st. They issued a “neutral” rating for the company. GMP Securities reaffirmed a “hold” rating and issued a $9.50 price target on shares of Aurora Cannabis in a report on Tuesday, February 12th. Cowen initiated coverage on Aurora Cannabis in a report on Tuesday, March 5th. They issued an “outperform” rating for the company. Jefferies Financial Group initiated coverage on Aurora Cannabis in a report on Monday, February 25th. They issued a “buy” rating for the company. Finally, TheStreet downgraded Aurora Cannabis from a “c” rating to a “d+” rating in a report on Monday, February 25th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $9.50.

The company has a quick ratio of 2.50, a current ratio of 3.31 and a debt-to-equity ratio of 0.08. The firm has a market cap of $8.06 billion, a PE ratio of 74.92 and a beta of 2.90.

Aurora Cannabis (NYSE:ACB) last announced its quarterly earnings results on Monday, February 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.02. The firm had revenue of $41.00 million during the quarter. Aurora Cannabis had a positive return on equity of 3.95% and a negative net margin of 57.54%. As a group, research analysts predict that Aurora Cannabis Inc will post -0.17 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. ETF Managers Group LLC acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $40,454,000. Norges Bank acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $30,915,000. TD Asset Management Inc. acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $16,657,000. JW Asset Management LLC acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $10,734,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $10,504,000. 8.16% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Investors Buy Aurora Cannabis (ACB) on Weakness” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/03/14/investors-buy-aurora-cannabis-acb-on-weakness.html.

Aurora Cannabis Company Profile (NYSE:ACB)

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Featured Story: Certificate of Deposit (CD)

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Aurora Cannabis (ACB) Shares Gap Up to $9.07

Aurora Cannabis Inc (NYSE:ACB)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $9.51, but …

Aurora Cannabis logoAurora Cannabis Inc (NYSE:ACB)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $9.51, but opened at $9.07. Aurora Cannabis shares last traded at $8.90, with a volume of 40759977 shares changing hands.

ACB has been the topic of several research reports. GMP Securities raised shares of Aurora Cannabis from a “hold” rating to a “buy” rating in a research note on Wednesday. TheStreet downgraded shares of Aurora Cannabis from a “c” rating to a “d+” rating in a research note on Monday, February 25th. Jefferies Financial Group assumed coverage on shares of Aurora Cannabis in a research note on Monday, February 25th. They issued a “buy” rating on the stock. Cowen assumed coverage on shares of Aurora Cannabis in a research note on Tuesday, March 5th. They set an “outperform” rating on the stock. Finally, Seaport Global Securities assumed coverage on shares of Aurora Cannabis in a research report on Thursday, February 21st. They set a “neutral” rating for the company. One analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $9.50.

The stock has a market capitalization of $8.06 billion, a price-to-earnings ratio of 74.50 and a beta of 2.90. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.50 and a current ratio of 3.31.

Aurora Cannabis (NYSE:ACB) last released its quarterly earnings results on Monday, February 11th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. Aurora Cannabis had a negative net margin of 57.54% and a positive return on equity of 3.95%. The firm had revenue of $41.00 million during the quarter. Analysts forecast that Aurora Cannabis Inc will post -0.17 earnings per share for the current year.

Several large investors have recently bought and sold shares of ACB. ETF Managers Group LLC acquired a new position in shares of Aurora Cannabis during the 4th quarter worth $40,454,000. Norges Bank acquired a new stake in Aurora Cannabis in the 4th quarter valued at about $30,915,000. TD Asset Management Inc. acquired a new stake in Aurora Cannabis in the 4th quarter valued at about $16,657,000. JW Asset Management LLC acquired a new stake in Aurora Cannabis in the 4th quarter valued at about $10,734,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in Aurora Cannabis in the 4th quarter valued at about $10,504,000. 8.16% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Modern Readers and is the property of of Modern Readers. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.modernreaders.com/news/2019/03/14/aurora-cannabis-acb-shares-gap-up-to-9-07.html.

Aurora Cannabis Company Profile (NYSE:ACB)

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

See Also: What is a Lock-Up Period?

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

GMP FirstEnergy with $15 Target Upgraded Aurora Cannabis Inc (ACB)’s Rating.

On Wednesday, 13 March Aurora Cannabis Inc (ACB) was increased by GMP FirstEnergy to a Buy. The firm has $15 PT given by broker’s professional …

GMP FirstEnergy Increased Aurora Cannabis Inc (ACB)’s Rating to Buy.

On Wednesday, 13 March Aurora Cannabis Inc (ACB) was increased by GMP FirstEnergy to a Buy. The firm has $15 PT given by broker’s professional analysts. This would suggest 67.22 % upside potential.

Ticker’s shares touched $8.97 during the last trading session after 1.12% change.Aurora Cannabis Inc. is downtrending after having declined 10.79% since March 14, 2018. ACB has 46.53 million volume or 84.63% up from normal. ACB underperformed the S&P 500 by 15.16%.

On May, 14. Investors expect Aurora Cannabis Inc. (NYSE:ACB) to reveal its quarterly earnings, according to Faxor. Analysts forecast $-0.05 earnings per share, which is $0.01 down or 25.00 % from 2018’s $-0.04 earnings per share. After $-0.04 earnings per share was published previous quarter, analysts now see negative EPS growth of 25.00 % for Aurora Cannabis Inc..

Aurora Cannabis Inc. produces and distributes medical cannabis products.The firm is valued at $9.03 billion. It is vertically integrated and horizontally diversified across various divisions of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.The P/E ratio is 41.52. The company’s products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products.

For more Aurora Cannabis Inc. (NYSE:ACB) news published briefly go to: Fool.com, Seekingalpha.com, Benzinga.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “3 Reasons 1 Top Analyst Gives a Thumbs-Down to Tilray – Motley Fool” published on March 13, 2019, “How do teen smoking risks affect pot stocks? – Seeking Alpha” on February 14, 2019, “Apple Inc. (NASDAQ:AAPL), (ACB) – General Electric Takes A Hit, Retailers Outperform Amid Broader Market Pause – Benzinga” with a publish date: March 06, 2019, “Aurora Cannabis: Can This Weed (Stock) Keep Growing? – Seeking Alpha” and the last “Constellation Brands Made The Right Move With Early Cannabis Investment (NYSE:STZ)(NYSE:CGC)(NYSE:ACB) – Benzinga” with publication date: February 13, 2019.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts